Retrospective analysis reveals SF3B1 mutations associate with shorter treatment time and higher risk in chronic lymphocytic leukemia, suggesting potential prognostic value.
Key Points
The research investigates the impact of SF3B1 mutations on treatment timing and overall survival in chronic lymphocytic leukemia.
Retrospective analysis of the DFCI CLL Database
Assessment of NGS data from 1,569 patients
Identified SF3B1 mutations and correlated with clinical outcomes
Used Kaplan–Meier and Cox regression for survival analysis
Evaluated the prevalence of other genetic risk factors like TP53 mutations and beta-2-microglobulin levels.
SF3B1 mutations were found in 11.8% of patients and were linked to a shorter median time to first treatment (57.2 months) compared to non-mutated patients (95.4 months)
Significant associations were found between SF3B1 mutations and higher Rai staging, elevated beta-2-microglobulin levels, and unmutated IGHV status
The SF3B1 mutation was an independent risk factor for shorter time to first treatment
Overall survival rates were similar between SF3B1 mutated and wild-type groups.